These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 36921239

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2019 May 07; 5(5):CD009219. PubMed ID: 31063591
    [Abstract] [Full Text] [Related]

  • 3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2014 Jul 01; (7):CD009219. PubMed ID: 24984156
    [Abstract] [Full Text] [Related]

  • 4. Platinum-induced hearing loss after treatment for childhood cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2016 Aug 03; 2016(8):CD010181. PubMed ID: 27486906
    [Abstract] [Full Text] [Related]

  • 5. The long-term impacts of hearing loss, tinnitus and poor balance on the quality of life of people living with and beyond cancer after platinum-based chemotherapy: a literature review.
    Phillips OR, Baguley DM, Pearson SE, Akeroyd MA.
    J Cancer Surviv; 2023 Feb 03; 17(1):40-58. PubMed ID: 36637633
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD009219. PubMed ID: 22592737
    [Abstract] [Full Text] [Related]

  • 8. Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.
    Okada H, Kitagawa K.
    Cancer Med; 2023 Apr 16; 12(7):7904-7910. PubMed ID: 36567514
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions.
    Tan WJT, Vlajkovic SM.
    Int J Mol Sci; 2023 Nov 20; 24(22):. PubMed ID: 38003734
    [Abstract] [Full Text] [Related]

  • 11. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
    Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM.
    Cancer Epidemiol; 2022 Aug 20; 79():102203. PubMed ID: 35724557
    [Abstract] [Full Text] [Related]

  • 12. COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
    Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E.
    Eur J Cancer; 2017 Dec 20; 87():75-83. PubMed ID: 29128692
    [Abstract] [Full Text] [Related]

  • 13. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2018 Jul 05; 7(7):CD010885. PubMed ID: 29975402
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin-induced ototoxicity: Updates on molecular mechanisms and otoprotective strategies.
    Tang Q, Wang X, Jin H, Mi Y, Liu L, Dong M, Chen Y, Zou Z.
    Eur J Pharm Biopharm; 2021 Jun 05; 163():60-71. PubMed ID: 33775853
    [Abstract] [Full Text] [Related]

  • 15. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
    Sriyapai T, Thongyai K, Phuakpet K, Vathana N, Buaboonnam J, Sanpakit K.
    Turk J Pediatr; 2022 Jun 05; 64(3):531-541. PubMed ID: 35899566
    [Abstract] [Full Text] [Related]

  • 16. Development and validation of a cisplatin dose-ototoxicity model.
    Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D.
    J Am Acad Audiol; 2012 Jun 05; 23(7):510-21. PubMed ID: 22992258
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I, Leclerc M, Côté M.
    J Otolaryngol Head Neck Surg; 2019 Jan 16; 48(1):4. PubMed ID: 30651130
    [Abstract] [Full Text] [Related]

  • 18. Baseline audiological profiling of South African females with cervical cancer: an important attribute for assessing cisplatin-associated ototoxicity.
    Paken J, Govender CD, Pillay M, Ayele BT, Sewram V.
    BMC Womens Health; 2021 Apr 20; 21(1):164. PubMed ID: 33879158
    [Abstract] [Full Text] [Related]

  • 19. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2016 Aug 08; (8):CD010885. PubMed ID: 27498707
    [Abstract] [Full Text] [Related]

  • 20. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E, Emami N, Alzahrani M, Bezdjian A, Gurberg J, Carret AS, Daniel SJ.
    Pediatr Blood Cancer; 2014 Nov 08; 61(11):2012-7. PubMed ID: 24976616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.